Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody Therapy

This publication has 42 references indexed in Scilit:

• THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITIS
  Rheumatology, 1995
• Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases
  Immunology Today, 1995
• Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.
  Journal of Clinical Investigation, 1994
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
  Molecular Immunology, 1993
• Tumor necrosis factor alpha is involved in mouse growth and lymphoid tissue development.
  The Journal of Experimental Medicine, 1992
• The importance of the t cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis
  Arthritis & Rheumatism, 1992
• Strategies of Anti‐Cytokine Monoclonal Antibody Development: Immunoassay of IL‐10 and IL‐5 in Clinical Samples
  Immunological Reviews, 1992
• Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
  Arthritis & Rheumatism, 1988
• Augmented interleukin‐1 production and hla–dr expression in the synovium of rheumatoid arthritis patients
  Arthritis & Rheumatism, 1988
• The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
  Arthritis & Rheumatism, 1988